1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Beijing Kawin Technology Share-Holding Co., Ltd. Class A

Beijing Kawin Technology Share-Holding Co., Ltd. Class A

SSSE:688687
16.05
CNY
-0.29
(-1.77%)
2.79BMarket Cap
Oct 31Next Earn
2012 Y
2013 Y
2014 Y
2015 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.28
2.35
2.61
2.69
4.2
5.82
6.78
6.73
7.04
6.81
8.48
7.35
7.77
- -
Basic EPS, GAAP
0.23
0.2
0.14
0.24
0.23
0.37
0.44
0.59
0.66
0.49
0.7
0.85
0.18
- -
Free Cash Flow per Basic Share
- -
-0.53
-0.5
-0.69
-0.36
0.08
0.44
0.7
0.45
0.35
-0.17
-0.97
-0.14
- -
Dividend per Share
0.05
0.08
0.11
0.06
0.01
- -
- -
- -
0.16
0.25
0.2
0.27
0.33
0.3
Book Value per Share
1.29
1.78
1.88
4.4
5.04
5.42
6.06
6.66
9.88
9.8
10.26
10.78
9.99
9.98
Tangible Book Value per Share
0.84
1.14
0.97
3.3
4.32
4.47
4.96
5.56
9.1
8.88
9.19
9.6
9.57
9.6
Basic Weighted Avg Shares
79
85
86
100
117
121
122
128
163
170
166
167
170
164
Sales/Revenue/Turnover
180
200
225
268
491
706
825
862
1,144
1,160
1,412
1,230
1,321
- -
Operating Margin (%)
11.58
12.72
8.79
10.89
3.54
7.33
8.63
10.37
7.48
6.79
10.68
13.15
14.6
- -
Depreciation Expense
- -
12
11
16
23
22
23
33
37
39
40
47
54
- -
Net Income, GAAP
18
17
12
24
27
45
54
76
107
83
117
142
31
- -
Effective Tax Rate (%)
25.8
21.69
18.59
11.84
19.71
15.83
25.11
19.16
20.2
17.5
6.13
9.99
25.07
- -
Profit Margin (%)
10.09
8.51
5.37
8.94
5.47
6.35
6.49
8.77
9.38
7.19
8.25
11.57
2.32
- -
Working Capital
50
18
-56
179
330
361
479
543
1,379
1,316
1,230
1,322
1,252
1,373
LT Debt
54
7
- -
- -
- -
- -
- -
- -
3
- -
28
162
263
234
Total Equity
163
221
240
546
612
655
772
854
1,687
1,682
1,785
1,880
1,740
1,741
Return on Invested Capital (%)
5.89
4.74
2.49
4.37
3.62
6.49
7.05
8.82
8.18
5.19
9.09
8.78
2.3
- -
Return on Capital (%)
8.99
5.79
4.03
5.16
5.36
7.23
7.58
9.3
9.15
5.14
5.46
6.27
1.06
- -
Return on Common Equity (%)
13.41
9.18
5.47
6.3
4.7
7.09
7.5
9.33
8.49
4.97
6.8
7.92
1.72
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
241
250
175
LT Borrowings
263
234
234
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
171
171
171
Market Capitalization
4,260
3,427
2,788

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,955
1,870
1,882
Cash, Cash Equivalents & STI
1,121
1,072
950
Accounts Receivable, Net
441
430
474
Inventories
136
128
132
Total Current Liabilities
702
621
508
Payables & Accruals
- -
- -
- -
ST Debt
241
250
175
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.66%
20.27%
-7.47%
Free Cash Flow
62.97%
41.55%
-85.4%
Net Income, GAAP
24.08%
0.62%
-78.51%
Sales/Revenue/Turnover
21.77%
10.06%
7.35%
Total Cash Common Dividend
- -
- -
24.9%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
213
384
414
220
1,230
2025
232
335
- -
394
1,321
2026
207
270
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
0.12
0.39
0.2
0.85
2025
0.15
0.13
- -
-0.43
0.18
2026
0.04
0.12
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.25
0.01
0.01
0.27
2025
0.01
0.31
- -
0.01
0.33
2026
0.01
0.26
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
De Sheng Zhou
Full Time Employees
617
Sector
Health technology
Industry
Biotechnology
Address
Building 3, No. 6, Rongjing East Street Beijing BE China 100176
IPO Date
Feb 8, 2021
Website
kawin.com.cn
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Beijing Kawin Technology Share-Holding Co., Ltd. (688687.SS) is a China-based biopharmaceutical company focused on viral and immune diseases, providing treatment solutions through its biotechnology platforms; core products include Recombinant Human Interferon α2b Injection (凯因益生), Compound Glycyrrhizin Capsules (凯因甘乐) and Tablets, Recombinant Human Interferon α2b Vaginal Effervescent Tablets (金舒喜), Coblopasvir Hydrochloride Capsules (凯力唯), Sofosbuvir Tablets (赛波唯), Peginterferon Alfa-2b Injection, and Pirfenidone Tablets, primarily targeting hepatitis C, liver diseases, and related viral conditions with both biological and chemical formulations produced across six GMP lines encompassing small volume parenteral solutions, lyophilized powders for injection, effervescent tablets, tablets, and capsules. Founded in 2008 and headquartered in the Beijing Economic-Technological Development Area (BDA), the company operates mainly in the domestic Chinese market with minimal overseas sales and exports to countries including the Philippines, Pakistan, Vietnam, Colombia, and Indonesia; it maintains subsidiaries in the United States and Singapore alongside marketing subsidiaries. Kawin listed on the Shanghai Stock Exchange STAR Market in February 2021 following strategic partnerships with investors such as Legend Capital, Haitong Capital, Cybernaut, and Lilly Asia Ventures; recent developments include the October 2024 agreement to acquire an additional 5% stake in Beijing Kawin Geling Biotechnology Co., Ltd. for CNY 10 million to strengthen its biotechnology portfolio, alongside ongoing R&D in innovative drugs, inclusion of its hepatitis C pan-genotype regimen in China's National Reimbursement Drug List, and receipt of international PIC/S GMP certification for certain chemical production lines.